Breaking News

Baxter to Acquire Chatham Therapeutics

April 2, 2014

Gains gene therapy programs for hemophilia treatments

Baxter International Inc. has entered an agreement to acquire Chatham Therapeutics for an initial payment of $70 million, and potential future payments based on certain development, regulatory and commercial milestones. With the acquisition, Baxter gains Chatham’s developmental gene therapy programs for the development and commercialization of treatments for hemophilia.
 
The two companies entered a collaboration in May 2012 to evaluate Chatham’s Biological Nano Particle (BNP) platform for potential treatments for hemophilia B, resulting in BAX 335, which is currently in Phase I/II development. Baxter will also have access to the previously partnered hemophilia B (FIX) program, a preclinical hemophilia A (FVIII) program, and the potential future application to additional hemophilia treatments.
 
''Chatham’s gene therapy platform technology offers the potential to redefine treatment of both hemophilia A and B,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. ''This technology will be highly complementary to our expanding pipeline of bleeding disorder treatments as we continue our pursuit of a bleed-free world.''
 
''Given Baxter’s long-standing commitment to innovative product development in hemophilia, we are confident that this transaction provides the best opportunity for the advancement of our BNP gene therapy platform technology for the benefit of hemophilia patients worldwide. The integration of Chatham’s next-generation technology and expertise, along with Baxter’s global marketing and distribution presence, is a combination we anticipate will support efficient delivery of a potential new class of therapeutics to the hemophilia market,'' said Jade Samulski, co-founder of Chatham and vice president of Asklepios BioPharmaceutical, Inc.
 
Following the acquisition, Chatham will maintain its licensing and development relationship with Asklepios BioPharmaceutical on the development of novel hemophilia therapeutic gene therapy candidates using the BNP platform.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016